Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
AnaptysBio (ANAB), a clinical-stage biotechnology company specializing in innovative immunology therapeutics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Daniel Faga, the company's president and chief executive officer, will deliver a presentation on Tuesday, January 14, 2025, at 4:30 PM PT / 7:30 PM ET.
The presentation will be accessible via live webcast through the investor section of the Anaptys website. Interested parties can access the webcast at http://ir.anaptysbio.com/events, and a replay will remain available for a minimum of 30 days after the event.
AnaptysBio (ANAB), un'azienda biotecnologica in fase clinica specializzata in terapie innovative per l'immunologia, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. Daniel Faga, presidente e amministratore delegato dell'azienda, terrà una presentazione martedì 14 gennaio 2025, alle 16:30 PT / 19:30 ET.
La presentazione sarà accessibile tramite una diretta streaming nella sezione investitori del sito web di Anaptys. Le parti interessate possono accedere allo streaming su http://ir.anaptysbio.com/events, e una registrazione sarà disponibile per un minimo di 30 giorni dopo l'evento.
AnaptysBio (ANAB), una empresa de biotecnología en etapa clínica especializada en terapias innovadoras de inmunología, ha anunciado su participación en la 43ª Conferencia Anual J.P. Morgan Healthcare. Daniel Faga, presidente y director ejecutivo de la compañía, presentará una conferencia el martes 14 de enero de 2025, a las 4:30 PM PT / 7:30 PM ET.
La presentación estará disponible a través de una transmisión en vivo en la sección de inversores del sitio web de Anaptys. Las partes interesadas pueden acceder a la transmisión en http://ir.anaptysbio.com/events, y se hará una repetición disponible por un mínimo de 30 días después del evento.
AnaptysBio (ANAB), 혁신적인 면역 치료제를 전문으로 하는 임상 단계 생명공학 회사가 제43회 JP모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 다니엘 파가 회사의 사장 겸 CEO가 2025년 1월 14일 화요일 오후 4시 30분 PT / 오후 7시 30분 ET에 발표를 진행합니다.
발표는 Anaptys 웹사이트의 투자자 섹션을 통해 생중계됩니다. 관심 있는 당사자는 http://ir.anaptysbio.com/events에서 생중계를 시청할 수 있으며, 이벤트 후 최소 30일 동안 재생이 가능합니다.
AnaptysBio (ANAB), une entreprise de biotechnologie en phase clinique spécialisée dans des thérapies immunologiques innovantes, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare. Daniel Faga, président et PDG de la société, fera une présentation mardi 14 janvier 2025, à 16h30 PT / 19h30 ET.
La présentation sera accessible par le biais d'une diffusion en direct dans la section investisseurs du site Web d'Anaptys. Les personnes intéressées peuvent accéder à la diffusion en direct à l'adresse http://ir.anaptysbio.com/events, et un enregistrement sera disponible pendant au moins 30 jours après l'événement.
AnaptysBio (ANAB), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf innovative immunologische Therapeutika spezialisiert hat, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz angekündigt. Daniel Faga, der Präsident und CEO des Unternehmens, wird am Dienstag, den 14. Januar 2025, um 16:30 Uhr PT / 19:30 Uhr ET eine Präsentation halten.
Die Präsentation wird über einen Live-Stream im Investorenbereich der Anaptys-Website zugänglich sein. Interessierte Parteien können den Live-Stream unter http://ir.anaptysbio.com/events abrufen, und eine Wiederholung wird mindestens 30 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025 at 4:30pm PT / 7:30pm ET.
A live webcast of the presentation will be available on the investor section of the Anaptys website at http://ir.anaptysbio.com/events. A replay of the webcast will be available for at least 30 days following the event.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a depleter and agonist targeting PD-1+ T cells, is in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. Other antibodies in its portfolio include ANB033, an anti-CD122 antagonist, in a Phase 1 trial and ANB101, a BDCA2 modulator, soon to enter clinical development. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an anti-PD-1 antagonist (Jemperli (dostarlimab-gxly)) and an anti-TIM-3 antagonist (cobolimab, GSK4069889). To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.
Contact:
Nick Montemarano
Senior Director, Investor Relations and Strategic Communications
858.732.0178
investors@anaptysbio.com
FAQ
When is AnaptysBio (ANAB) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch AnaptysBio's J.P. Morgan Healthcare Conference presentation?
How long will the replay of ANAB's J.P. Morgan Healthcare Conference presentation be available?
Who will be presenting for AnaptysBio at the 2025 J.P. Morgan Healthcare Conference?
What is AnaptysBio's primary business focus as presented at the J.P. Morgan Conference?
